Anti-inflammatory properties of the novel antitumor agent Yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production

Paola Allavena, Mauro Signorelli, Marcello Chieppa, Eugenio Erba, Giancarlo Bianchi, Federica Marchesi, Chiara Omero Olimpio, Claudia Bonardi, Annalisa Garbi, Andrea Lissoni, Filippo De Braud, José Jimeno, Maurizio D'Incalci

Research output: Contribution to journalArticlepeer-review

Abstract

Yondelis (Trabectedin) is a novel antitumor agent of marine origin extracted from the tunicate Ecteinascidia turbinata. This original compound is active against several human tumors including sarcoma and ovarian and breast adenocarcinoma, as evidenced in phase II clinical trials in advanced multitreated patients. Yondelis is a DNA minor groove binder that blocks cell cycle and interferes with inducible gene transcription in a selective manner. In this study, we investigated the immunomodulatory properties of Yondelis on leukocytes. Human blood monocytes were highly susceptible in vitro to its cytotoxic effect and underwent apoptosis at pharmacologically relevant concentrations (5 nmol/L), whereas lymphocytes were up to 5-fold less sensitive. Macrophages differentiated in vitro with macrophage colony-stimulating factor and tumor-associated macrophages (TAM), isolated from patients with ovarian cancer, were also susceptible. At subcytotoxic concentrations, Yondelis inhibited the in vitro differentiation of monocytes to macrophages. In tumor-treated patients, drug infusion caused a selective decrease of monocyte counts and of ex vivo macrophage differentiation. The in vitro production of two proinflammatory mediators, CCL2 and IL-6, was markedly reduced by Yondelis in monocytes, macrophages, TAM, and freshly isolated ovarian tumor cells. The chemokine CCL2 is the major determinant of monocyte recruitment at tumor sites, whereas IL-6 is a growth factor for ovarian tumors. In view of the protumor activity of TAM and of the strong association between chronic inflammation and cancer progression, the inhibitory effect of Yondelis on macrophage viability, differentiation, and cytokine production is likely to contribute to the antitumor activity of this agent in inflammation-associated human tamors.

Original languageEnglish
Pages (from-to)2964-2971
Number of pages8
JournalCancer Research
Volume65
Issue number7
DOIs
Publication statusPublished - Apr 1 2005

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Anti-inflammatory properties of the novel antitumor agent Yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production'. Together they form a unique fingerprint.

Cite this